Literature DB >> 27232533

SMARCAD1 knockdown uncovers its role in breast cancer cell migration, invasion, and metastasis.

Elham Al Kubaisy1, Kholoud Arafat1, Olivier De Wever2, Ahmed H Hassan3, Samir Attoub1,4.   

Abstract

OBJECTIVE: Breast cancer is the most common cancer seen in women worldwide and breast cancer patients are at high risk of recurrence in the form of metastatic disease. Identification of genes associated with invasion and metastasis is crucial in order to develop novel anti-metastasis targeted therapy. It has been demonstrated that the DEAD-BOX helicase DP103 was implicated in breast cancer invasion and metastasis. SMARCAD1 is also a DEAD/H box-containing helicase, suggested to play a role in genetic instability. However, its involvement in cancer migration, invasion, and metastasis has never been explored. RESEARCH DESIGN AND METHODS: Using two different designs of shRNA targeting SMARCAD1, we investigated the impact of SMARCAD1 knockdown on the migration, invasion, and metastasis potential of the breast cancer cells MDA-MB-231 and T47D.
RESULTS: We observed that SMARCAD1 knockdown in the invasive breast cancer cells MDA-MB-231, unlike in the non-invasive breast cancer cells T47D, was associated with an increased cell-cell adhesion and a significant decrease in cell migration, invasion, and metastasis due at least in part to a strong inhibition of STAT3 phosphorylation.
CONCLUSIONS: These results indicate that SMARCAD1 is involved in breast cancer metastasis and can be a promising target for metastatic breast cancer therapy.

Entities:  

Keywords:  Breast cancer; SMARCAD1; STAT3; invasion; metastasis; migration

Mesh:

Substances:

Year:  2016        PMID: 27232533     DOI: 10.1080/14728222.2016.1195059

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  9 in total

1.  A transcriptomic insight into the impacts of mast cells in lung, breast, and colon cancers.

Authors:  Eun-A Ko; Kenton M Sanders; Tong Zhou
Journal:  Oncoimmunology       Date:  2017-08-08       Impact factor: 8.110

2.  SMARCAD1 Promotes Pancreatic Cancer Cell Growth and Metastasis through Wnt/β-catenin-Mediated EMT.

Authors:  Furao Liu; Zebin Xia; Meichao Zhang; Jiping Ding; Yang Feng; Jianwei Wu; Yun Dong; Wei Gao; Zengwei Han; Yuanhua Liu; Yuan Yao; Dong Li
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

3.  Over-expression of CDX2 alleviates breast cancer by up-regulating microRNA let-7b and inhibiting COL11A1 expression.

Authors:  Hongbin Wang; Yanlv Ren; Cheng Qian; Jiaxin Liu; Ge Li; Zhigao Li
Journal:  Cancer Cell Int       Date:  2020-01-10       Impact factor: 5.722

4.  PTC-209 Anti-Cancer Effects Involved the Inhibition of STAT3 Phosphorylation.

Authors:  Shahrazad Sulaiman; Kholoud Arafat; Rabah Iratni; Samir Attoub
Journal:  Front Pharmacol       Date:  2019-10-21       Impact factor: 5.810

5.  SMARCAD1-mediated active replication fork stability maintains genome integrity.

Authors:  Calvin Shun Yu Lo; Marvin van Toorn; Vincent Gaggioli; Mariana Paes Dias; Yifan Zhu; Eleni Maria Manolika; Wei Zhao; Marit van der Does; Chirantani Mukherjee; João G S C Souto Gonçalves; Martin E van Royen; Pim J French; Jeroen Demmers; Ihor Smal; Hannes Lans; David Wheeler; Jos Jonkers; Arnab Ray Chaudhuri; Jurgen A Marteijn; Nitika Taneja
Journal:  Sci Adv       Date:  2021-05-05       Impact factor: 14.136

6.  Butein and Frondoside-A Combination Exhibits Additive Anti-Cancer Effects on Tumor Cell Viability, Colony Growth, and Invasion and Synergism on Endothelial Cell Migration.

Authors:  Shahrazad Sulaiman; Kholoud Arafat; Aya Mudhafar Al-Azawi; Noura Abdulraouf AlMarzooqi; Shamsa Nasser Ali Hussain Lootah; Samir Attoub
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

7.  Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma.

Authors:  Qing Wu; Yangzhi Hu; Qinghui Ma; Shanglin Yang; Junpeng Chen; Shunqian Wen; Guanqun Liao
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.501

Review 8.  3D chromatin architecture and transcription regulation in cancer.

Authors:  Siwei Deng; Yuliang Feng; Siim Pauklin
Journal:  J Hematol Oncol       Date:  2022-05-04       Impact factor: 23.168

9.  HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer.

Authors:  Feng-Jiao Wang; Yan-Hua Jing; Chien-Shan Cheng; Zhang-Qi Cao; Ju-Ying Jiao; Zhen Chen
Journal:  BMC Med Genomics       Date:  2021-07-27       Impact factor: 3.063

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.